Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more
Zhejiang Orient Gene Biotech Co Ltd (688298) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.01 Billion CNY
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has total liabilities worth CN¥1.01 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Orient Gene Biotech Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥444.73 Million |
|
Molinos Agro SA
BA:MOLA
|
Argentina | AR$870.57 Billion |
|
Syncmold Enterprise Corp
TW:1582
|
Taiwan | NT$5.20 Billion |
|
Jasa Marga Tbk
JK:JSMR
|
Indonesia | Rp97.63 Trillion |
|
AGF Management Limited
PINK:AGFMF
|
USA | $509.56 Million |
|
BKS Bank AG
VI:BKS
|
Austria | €9.04 Billion |
|
Pet Acquisition LLC
NASDAQ:WOOF
|
USA | $4.05 Billion |
|
Sprout Social Inc
NASDAQ:SPT
|
USA | $319.64 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Zhejiang Orient Gene Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Orient Gene Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.30 Billion | -9.89% |
| 2023-12-31 | CN¥1.45 Billion | -39.25% |
| 2022-12-31 | CN¥2.38 Billion | +14.01% |
| 2021-12-31 | CN¥2.09 Billion | +86.14% |
| 2020-12-31 | CN¥1.12 Billion | +944.66% |
| 2019-12-31 | CN¥107.38 Million | -17.15% |
| 2018-12-31 | CN¥129.62 Million | +6.94% |
| 2017-12-31 | CN¥121.20 Million | -14.82% |
| 2016-12-31 | CN¥142.28 Million | -- |